USP14 inhibitor VLX1570 was the first DUB inhibitor to enter clinical trials for multiple myeloma therapy, but was deferred due to pulmonary toxicity (Wang et al., 2015; Rowinsky et al., 2020). This evidence concerns the gene ZUP1 and plasma cell myeloma.